title: Silencing of integrin-linked kinase suppresses in vivo tumorigenesis             of human ovarian carcinoma cells.
abstract: Integrin-linked kinase (ILK) plays a role in the regulation of multiple             cellular functions (e.g., promoting cell migration and proliferation, but inhibiting             cell adhesion). This study investigated the inhibitory effects of ILK gene knockdown             on the regulation of in vivo tumorigenesis of human ovarian carcinoma cells in             nude mouse xenografts. HO-8910 cells were transfected with an ILK antisense oligonucleotide             (ILK-ASO) to silence the ILK gene. Expression of ILK mRNA and protein was evaluated             by RT-PCR and western blotting, respectively. The cell cycle was assessed by flow             cytometric analysis. Cells with or without ILK-ASO transfection were subcutaneously             injected into nude mice. The mouse body weight, tumor formation, tumor size and             tumor weight were determined up to 30 days after inoculation. Tumor cells transfected             with ILK-ASO had significantly decreased ILK mRNA and protein expression (P<0.01)             when compared to the control cells. ILK gene silencing significantly increased             the number of cells in the G0/G1 phase (67.61 vs. 43.29%, χ2=1197.15, P<0.01).             After tumor cell inoculation, tumor cells transfected with ILK-ASO showed significantly             delayed tumor formation when compared to control (9.10±0.74 vs. 5.30±0.67 days,             respectively; P<0.01). In addition, tumor growth was suppressed in the 30 days             following inoculation (P<0.01 compared with the controls). The average tumor             weight in the ILK-ASO group was statistically lower than that of the control group             (1.29±0.11 vs. 1.57±0.13 g, respectively; P<0.01). This study demonstrated             that ILK-ASO transfection efficiently downregulated ILK expression in human ovarian             carcinoma HO-8910 cells and that ILK gene silencing suppressed tumor growth in             nude mice xenografts.
authors: Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin 150081, Heilongjiang, PR China. liqi@ems.hrbmu.edu.cn
authors: Qi
authors: Q
authors: Li
authors: Chen
authors: C
authors: Li
authors: Yun-Yan
authors: YY
authors: Zhang
authors: Wei
authors: W
authors: Chen
authors: Jun-Li
authors: JL
authors: Lv
authors: Jing
authors: J
authors: Sun
authors: Qing-Shan
authors: QS
authors: You
mesh_terms: D000818:Animals; D063646:Carcinogenesis; D002277:Carcinoma / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D005260:Female; D059585:G1 Phase Cell Cycle Checkpoints; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D034622:RNA Interference; D012333:RNA, Messenger / Q000378:metabolism; D034741:RNA, Small Interfering / Q000378:metabolism / Q000627:therapeutic use; D014183:Transplantation, Heterologous; D000099200:Scaffold Protein ILK
chemical_list: D017346:Protein Serine-Threonine Kinases; D012333:RNA, Messenger; D034741:RNA, Small Interfering; D000099200:Scaffold Protein ILK